JAK1 and Alzheimer disease: Oral formulations of JAK inhibitors, specifically baricitinib (JAK1/2), abrocitinib (JAK1), and upadacitinib (JAK1), have shown efficacy by achieving primary and secondary endpoints across multiple clinical studies focusing on moderate-to-severe AD.